Skip to main content

Advertisement

Table 4 Mean homocysteine concentration at follow up* according to treatment group and fracture outcomes

From: The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

  With fracture mean (standard deviation) Without fracture mean (standard deviation) Difference, (95% confidence interval) P-value (paired t-test)
Homocysteine (micromol/L     
Placebo (n = 584) 15.7 (5.9) (n = 23) 14.2 (6.1) (n = 561) −1.52 (−4.08,1.04) 0.2447
B-Vitamins (n =580) 11.7 (9.6) (n = 18) 10.5 (4.6) (n = 562) −1.17 (−3.46,1.11) 0.3118
  1. * The difference between baseline and follow-up Homocysteine levels were also compared between patients with and without facture. The differences are not significant, either (data not shown).
  2. Note: Only a small subset of patients (14.3%) had homocysteine levels measured at final follow up.